PortfoliosLab logo
Acumen Pharmaceuticals, Inc. (ABOS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00509G2093

CUSIP

00509G209

IPO Date

Jul 1, 2021

Highlights

Market Cap

$106.94M

EPS (TTM)

-$1.38

Total Revenue (TTM)

$290.00K

Gross Profit (TTM)

$162.00K

EBITDA (TTM)

-$75.48M

Year Range

$1.70 - $5.09

Target Price

$10.80

Short %

3.10%

Short Ratio

6.61

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Acumen Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%AugustSeptemberOctoberNovemberDecember
-25.50%
5.54%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Acumen Pharmaceuticals, Inc. had a return of 0.00% year-to-date (YTD) and -55.21% in the last 12 months.


ABOS

YTD

0.00%

1M

-24.23%

6M

-24.23%

1Y

-55.21%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.00%

1M

-2.50%

6M

6.76%

1Y

23.31%

5Y*

12.57%

10Y*

11.09%

*Annualized

Monthly Returns

The table below presents the monthly returns of ABOS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-17.19%35.53%-6.03%-20.49%-8.70%-17.69%36.36%-16.97%-9.49%16.13%-21.18%-55.21%
202321.67%-19.79%-22.96%-4.93%27.72%-2.43%53.85%-18.65%-31.06%-54.94%28.34%60.00%-28.89%
2022-24.26%14.45%-33.28%-1.28%-8.29%32.77%15.74%4.60%76.27%-31.01%-17.92%-4.93%-20.12%
2021-22.99%15.76%-17.08%-5.45%-43.77%-14.43%-66.37%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABOS is 12, meaning it’s performing worse than 88% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ABOS is 1212
Overall Rank
The Sharpe Ratio Rank of ABOS is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of ABOS is 1313
Sortino Ratio Rank
The Omega Ratio Rank of ABOS is 1616
Omega Ratio Rank
The Calmar Ratio Rank of ABOS is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ABOS is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Acumen Pharmaceuticals, Inc. (ABOS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for ABOS, currently valued at -0.75, compared to the broader market-4.00-2.000.002.00-0.751.84
The chart of Sortino ratio for ABOS, currently valued at -1.02, compared to the broader market-4.00-2.000.002.004.00-1.022.48
The chart of Omega ratio for ABOS, currently valued at 0.89, compared to the broader market0.501.001.502.000.891.34
The chart of Calmar ratio for ABOS, currently valued at -0.60, compared to the broader market0.002.004.006.00-0.602.75
The chart of Martin ratio for ABOS, currently valued at -1.47, compared to the broader market0.005.0010.0015.0020.0025.00-1.4711.85
ABOS
^GSPC

The current Acumen Pharmaceuticals, Inc. Sharpe ratio is -0.75. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Acumen Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember
-0.75
1.84
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Acumen Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember
-91.52%
-3.43%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Acumen Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acumen Pharmaceuticals, Inc. was 91.52%, occurring on Dec 31, 2024. The portfolio has not yet recovered.

The current Acumen Pharmaceuticals, Inc. drawdown is 91.52%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.52%Jul 6, 2021879Dec 31, 2024

Volatility

Volatility Chart

The current Acumen Pharmaceuticals, Inc. volatility is 17.20%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%AugustSeptemberOctoberNovemberDecember
17.20%
4.15%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Acumen Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Acumen Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items